






S3 Fig. Effective engraftment of human PBMC derived T cells in MPC iPDX mouse peripheral blood. (A) Representative flow cytometry plots are shown for MPC model CD3⁺CD45⁺ T lymphocytes from PDX mice (left), iPDX mice (middle). Data from samples collected at 2 weeks. (B) Bar graph of the average % of CD3⁺CD45⁺ cells (right). (C) Flow cytometry plots for CD4⁺ and CD8⁺ T lymphocytes from all iPDX mice (n=3). Data from samples collected at 2 weeks. (D) The change in the average % of human T lymphocytes from early (2 week) to late (7 weeks) engraftment are shown for MPC CD3⁺CD45⁺ T lymphocytes (left), CD8⁺ T lymphocytes (middle) and CD4⁺ T lymphocytes (right). (E) PD-1⁺CD4⁺ T lymphocytes (left) PD-1⁺CD8⁺ T lymphocytes (right). T lymphocytes from healthy human donor blood (grey histogram, left) and iPDX blood (empty histogram, right). (F) Bar graph showing average percentage of PD-1⁺CD4⁺ and CD8⁺ T lymphocytes. Data from samples collected at 7 weeks. The values represent the percentage of human CD3, CD4 and CD8 population in iPDX mice peripheral blood. Representative averages of per group (n=2) are shown. *P<0.05 and **P < 0.005.

A Engraftment in peripheral blood at 2 weeks**B** Engraftment at 2 weeks**C** Engraftment in peripheral blood at 2 weeks**D****E**Peripheral blood engrafted CD3⁺ at 7 wks**F**Peripheral blood engrafted CD3⁺ at 7 wks